Regenerative Medicine Programme: Tools and Technologies will see the TSB, the Medical Research Council (MRC), the Biotechnology and Biological Sciences Research Council (BBSRC), and EPSRC invest up to £8m in collaborative research and development projects.
The intention is to establish consortia that address generic challenges in the development of cell-based therapies and will lead to demonstrators that are commercially viable.
The TSB said in a statement that applications must be industrially led and are expected to consist of academic, industrial and end-user collaborators.
Through the Regenerative Medicine Programme: Developing Therapeutics 2 competition, the board is to invest up to £2.5m in commercial research and development projects in the area of regenerative-medicine therapeutics.
This will be aimed at supporting businesses in the pre-clinical, and particularly clinical, development of regenerative-medicine therapeutics. These must be collaborative and led by a business.
The two-stage competitions open on 14 March 2011 and compulsory expressions of interest must be submitted by 20 April 2011. The deadline for receipt of full applications is 20 July 2011.
Oxa launches autonomous Ford E-Transit for van and minibus modes
I'd like to know where these are operating in the UK. The report is notably light on this. I wonder why?